StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
BNRBurning Rock Biotech Ltd
stockpulse.co.kr
Nasdaq
$11.98▼ 0.62%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $126.3MShares out 10.6M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

1
  • 9.10Pre-market26.09.10 20:01
    6-KKey event#●●●#●●●

    Burning Rock Biotech Ltd

    Burning Rock Biotech reported revenue of $19.9 million (RMB 134.7 million) and a net loss of $2.7 million (RMB 18.4 million) for the second quarter of 2026. While total revenue decreased by 9.3% year-over-year, the in-hospital business segment showed a 7.4% growth, indicating a sequential recovery.…more

    $11.98-0.62%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare

News

GlobeNewswire
  • 9.10Pre-market26.09.10 20:17
    Bullish#●●●#●●●

    Burning Rock Biotech Reports Q2 Revenue Decline and Increased Net Loss

    Burning Rock Biotech's second-quarter revenue fell 9.3% year-over-year, while net loss widened to 18.4 million RMB. Despite growth in the in-hospital business, a significant decline in pharma R&D services contributed to the overall weak financial performance.…more

    $11.98-0.62%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire